Panelists discuss the prevention of the skeletal-related events associated with androgen deprivation therapy-related bone mineral density loss in patients with prostate cancer.
To view more from this discussion, visit onclive.com/peer-exchange/treating-mcrpc
- Preventing Skeletal-Related Events in Prostate Cancer ( Download)
- Identification and Prevention of Skeletal-Related Events ( Download)
- Reducing Skeletal-Related Events in Prostate Cancer ( Download)
- Optimizing Bone Health in Patients with Prostate Cancer ( Download)
- Advances in prevention and treatment of bone metastases in prostate cancer ( Download)
- Bone Metastases and Mortality ( Download)
- Bone Health in Prostate Cancer ( Download)
- CRPC: Preventing Complications With Bone-Targeted Agents ( Download)
- Management of Bone Metastases and Bone Health in Patients With Prostate Cancer ( Download)
- Updates on Managing Bone Disease in Multiple Myeloma ( Download)
- Bone Metastases in CRPC: Prognostic for Survival ( Download)
- Bone Targeted Agents in Metastatic Prostate Cancer: Denosumab, Bisphosphonates and Radium-223 ( Download)
- Putting the Brakes on Prostate Cancer Progression in Bone ( Download)
- Bone Metastases and Mortality: Can We Be Doing More ( Download)
- Preventing Bone Complications From Bone Metastases ( Download)